Sort   by:  
 Page size 
TranscriptomicsRescue of chloride and bicarbonate transport by elexacaftor-ivacaftor-tezacaftor in organoid-derived CF intestinal and cholangiocyte monolayers
In cystic fibrosis (CF), loss of CF transmembrane conductance regulator (CFTR)-dependent bicarbonate secretion precipitates the accumulation of viscous mucus in the lumen of respiratory and gastrointestinal epithelial tissues. We investigated whether the combination of elexacaftor (ELX), ivacaftor (...
ORGANISM(S): Homo sapiens 
2021-12-14 | GSE182347 | GEO
UnknownElexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Not available
S-EPMC7282384 | biostudies-literature
UnknownRegulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy.
Not available
S-EPMC9978140 | biostudies-literature
UnknownRechallenge of Elexacaftor/Tezacaftor/Ivacaftor After Skin Rash in Two Pediatric Patients
Not available
S-EPMC9268115 | biostudies-literature
GenomicsRescue of chloride and bicarbonate transport by elexacaftor-ivacaftor-tezacaftor in organoid-derived CF intestinal and cholangiocyte monolayers
Rescue of chloride and bicarbonate transport by elexacaftor-ivacaftor-tezacaftor in organoid-derived CF intestinal and cholangiocyte monolayers
PRJNA755978 | ENA
Genomics
Sputum microbiota in people with cystic fibrosis starting on Elexacaftor/Tezacaftor/Ivacaftor
PRJNA934375 | ENA
ProteomicsLongitudinal Effects of Elexacaftor/Tezacaftor/Ivacaftor on Sputum Viscoelastic Properties, Airway Infection and Inflammation in Patients with Cystic Fibrosis
Rationale: We recently demonstrated that the triple combination CFTR modulator therapy elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) improves lung ventilation and airway mucus plugging determined by multiple-breath washout and magnetic resonance imaging in CF patients with at least one F508del alle...
ORGANISM(S): Homo sapiens (Human) 
2023-06-22 | PXD041844 | Pride
Disease Cystic fibrosis Proteome Elexacaftor/tezacaftor/ivacaftor Dda Sputum Label free 
UnknownPhysiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19.
Not available
S-EPMC9087007 | biostudies-literature
UnknownPhase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment.
Not available
S-EPMC9633523 | biostudies-literature
UnknownTherapeutic Drug Monitoring of Elexacaftor, Tezacaftor, and Ivacaftor in Adult People with Cystic Fibrosis.
Not available
S-EPMC11508966 | biostudies-literature
Sort   by:  
 Page size